Complexity made simple in diffuse large B-cell lymphoma

Clinical Cancer Research

Volumn 15, Issue 17, 2009, Pages 5291-5293

  Aster, Jon ^a   Kutok, Jeffery ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GCET1 PROTEIN; INTERFERON REGULATORY FACTOR 4; PREDNISONE; PROTEIN; PROTEIN BCL 6; RITUXIMAB; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP1; UNCLASSIFIED DRUG; VINCRISTINE;

ALGORITHM; CANCER CHEMOTHERAPY; CANCER SURVIVAL; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; NOTE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; TREATMENT RESPONSE;

B-LYMPHOCYTES; DNA-BINDING PROTEINS; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERFERON REGULATORY FACTORS; LYMPHOMA, LARGE B-CELL, DIFFUSE; NEOPLASM PROTEINS; NEPRILYSIN; REPRESSOR PROTEINS; SERPINS;

EID: 69949098407     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1444     Document Type: Note

References (12)

1. Choi WLW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009;15:5494-5502
2. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511 (Pubitemid 30082188)
3. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-1947 (Pubitemid 34651353)
4. Wright G, Tan B, Rosenwald A, Hurt EM, Wiestner A, Staudt L. A gene expressionbased method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 2003;100:9991-9996 (Pubitemid 37087056)
5. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-994
6. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282
7. Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009;113:6069-6076
8. Moskowitz CH, Zelenetz AD, Kewalramani T, et al. Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL. Blood 2005;106:3383-3385 (Pubitemid 41609171)
9. Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008;359:1995-2004.
10. Ross JS, Hatzis C, Symmans WF, Pusztai L, Hortobagyi GN. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist 2008;13:477-493 (Pubitemid 351872866)
11. Taylor CR, Levenson RM. Quantification of immunohistochemistry-issues concerning methods, utility and semiquantitative assessment II. Histopathology 2006;49:411-424 (Pubitemid 44401549)
12. Walker RA. Quantification of immunohistochemistry-issues concerning methods, utility and semiquantitative assessment I. Histopathology 2006;49:406-410 (Pubitemid 44401548)